{ "ok": true, "cik": "1022079", "ticker": "DGX", "name": "Quest Diagnostics Inc", "filings": [ { "form": "8-K", "filed": "2026-10-06", "items": [ "5.02 Departure or Election of Directors; Appointment of Officers" ], "url": "https://www.sec.gov/Archives/edgar/data/1022079/000094787126000922/0000947871-26-000922-index.htm" }, { "form": "10-Q", "filed": "2026-07-23", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1022079/000102207926000070/0001022079-26-000070-index.htm" }, { "form": "8-K", "filed": "2026-07-23", "items": [ "2.02 Results of Operations and Financial Condition", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1022079/000102207926000067/0001022079-26-000067-index.htm" }, { "form": "8-K", "filed": "2026-05-21", "items": [ "5.07 Submission of Matters to a Vote of Security Holders" ], "url": "https://www.sec.gov/Archives/edgar/data/1022079/000102207926000052/0001022079-26-000052-index.htm" }, { "form": "8-K", "filed": "2026-05-08", "items": [ "1.01 Entry into a Material Definitive Agreement", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1022079/000110465926057938/0001104659-26-057938-index.htm" }, { "form": "8-K", "filed": "2026-05-01", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1022079/000110465926054141/0001104659-26-054141-index.htm" } ], "events12m": 10, "healthWatch": { "window": "last 12 months", "since": "2025-10-07", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 2, "latest": { "filed": "2026-10-06", "url": "https://www.sec.gov/Archives/edgar/data/1022079/000094787126000922/0000947871-26-000922-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001022079.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1022079" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets and no trading recommendations.", "edgar": "🫧 Edgar looked up Quest Diagnostics Inc ($DGX). Last filing: 8-K (5.02 Departure or Election of Directors; Appointment of Officers), 2026-10-06. 10 event filings (8-K) in the past twelve months.", "auditor": { "changes": [], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 11035000000, "revenueGrowth1y": 0.11780794165316055, "revenueGrowthPerYear": 0.005675453314268886, "yearsOfData": 5, "operatingMargin": 0.14100589034888988, "operatingMarginPrior": 0.1363452188006483, "netMargin": 0.09478930675124604, "operatingCashFlow": 1886000000, "capitalSpending": 527000000, "freeCashFlow": 1359000000, "researchAndDevelopment": null, "researchShareOfRevenue": null, "cash": 420000000, "longTermDebt": 5671000000, "longTermDebtChange": -0.08782370918449411, "revenueHistory": [ { "fiscalYearEnd": "2021-12-31", "revenue": 10788000000 }, { "fiscalYearEnd": "2022-12-31", "revenue": 9883000000 }, { "fiscalYearEnd": "2023-12-31", "revenue": 9252000000 }, { "fiscalYearEnd": "2024-12-31", "revenue": 9872000000 }, { "fiscalYearEnd": "2025-12-31", "revenue": 11035000000 } ], "totalEquity": 7170000000, "totalAssets": 16225000000, "equityRatio": 0.4419106317411402, "returnOnEquity": 0.14588563458856346, "dividendsPaid": 353000000, "payoutRatio": 0.33747609942638623, "dividendPerShare": 1.8, "dividendYearsRising": 7, "dividendCut": false, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "earningsPerShare": 8.87, "sharesOutstanding": 113000000, "bookValuePerShare": 63.45132743362832, "revenuePerShare": 97.65486725663717, "range80": { "low": 10250700918.340801, "high": 12864129906.654016, "baseline": 11891556686.772013, "n": 1471, "band": "b10", "bandLabel": "$10B+", "method": "v4.1", "credibility": 0.5, "growthYears": 4, "ownVolatility": 0.09748860683773106, "classVolatility": 0.06659579566308972, "volatility": 0.08348361654588791 }, "ifPaceHeld": { "low": 10250700918.340801, "high": 12864129906.654016 } }, "edgarette": "🔖 Exposure: revenue $11.0B (FY2025), total debt $5.7B. Experience: revenue up 11.8% on the year, up 0.6% a year over 4 years; operating margin 14.1%, up from 13.6%. Soundness: equity 44.2% of assets, return on equity 14.6%, payout 33.7% of profit, dividend per share up 7 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $10.3B and $12.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $9.3B to $14.1B. A statistical range, not company guidance. Against peers (17 filers, $50M+ revenue, services-medical laboratories): operating margin 14.1% against a -12.4% median; growth 11.8% against 13.8%.", "peers": { "sic": 8071, "sicDescription": "Services-Medical Laboratories", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "8071", "growth": [ 0.1383, 17 ], "opMargin": [ -0.1244, 17 ], "equityRatio": [ 0.6525, 17 ], "returnOnEquity": [ -0.0705, 15 ] }, "summary": "Quest Diagnostics (DGX) grew revenue 11.8% in FY2025 to $11.0 billion, operating margin 14.1% against a -12.4% median for services-medical laboratories, equity 44.2% of assets, and dividend per share up 7 years running. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
Quest Diagnostics Inc against its own record and its peers
Operating marginPeer median -12.4%14.1%Revenue, on the yearPeer median 13.8%11.8%Equity of assetsPeer median 65.3%44.2%Return on equityPeer median -7.0%14.6%Payout of profit33.7%Gold tick: the median of 15–17 peers with $50M+ revenue in services-medical laboratories
", "chartHorizon": "
Handed back now, or kept to compound · of each dollar of profit
33.7% paid out66.3% keptHanded back per share$1.8up 7 years runningGrowth its own profit can fund9.7%managed 11.8% last year

Gold paid out, navy kept. Kept share × return on equity = the growth it can fund itself. Facts from the filings, not a recommendation.

", "backtest": { "tests": 15, "hits": 11, "rate": 0.7333333333333333, "method": "v4", "byYear": { "2011": [ 1, 1 ], "2012": [ 1, 1 ], "2013": [ 1, 1 ], "2014": [ 1, 1 ], "2015": [ 1, 1 ], "2016": [ 1, 1 ], "2017": [ 1, 1 ], "2018": [ 1, 1 ], "2019": [ 1, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 0, 1 ], "2023": [ 1, 1 ], "2024": [ 0, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-10-07T14:22:46.846Z", "hash": "8c1a5e4659ddf606", "status": "open" }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Quest Diagnostics (DGX) grew revenue 11.8% in FY2025 to $11.0 billion, operating margin 14.1% against a -12.4% median for services-medical laboratories, equity 44.2% of assets, and dividend per share up 7 years running. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 11035000000, "totalDebt": 5671000000, "cash": 420000000 }, "experience": { "revenueGrowth1y": 0.11780794165316055, "revenueGrowthPerYear": 0.005675453314268886, "operatingMargin": 0.14100589034888988, "operatingMarginPrior": 0.1363452188006483, "netMargin": 0.09478930675124604, "freeCashFlow": 1359000000 }, "soundness": { "equityRatio": 0.4419106317411402, "returnOnEquity": 0.14588563458856346, "payoutRatio": 0.33747609942638623, "dividendPerShare": 1.8, "dividendYearsRising": 7, "dividendCut": false, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 8071, "sicDescription": "Services-Medical Laboratories", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "8071", "growth": [ 0.1383, 17 ], "opMargin": [ -0.1244, 17 ], "equityRatio": [ 0.6525, 17 ], "returnOnEquity": [ -0.0705, 15 ] }, "credibility": { "auditedYears": 5, "weight": "reasonable", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": null }, "healthWatch": { "window": "last 12 months", "since": "2025-10-07", "signals": [ { "code": "5.02", "label": "Director or officer change", "count": 2, "latest": { "filed": "2026-10-06", "url": "https://www.sec.gov/Archives/edgar/data/1022079/000094787126000922/0000947871-26-000922-index.htm" } } ], "note": "Events the company itself filed with the SEC, most serious first. Shown beside the figures; they do not change the range or its receipt." }, "range": { "low": 10250700918.340801, "high": 12864129906.654016, "baseline": 11891556686.772013, "coverage": 0.8, "method": "v4.1", "basis": "next fiscal year revenue: baseline = revenue x (1 + mean of one-year and three-year pace); width = the company's own volatility of yearly growth, credibility-weighted against its size class (Buhlmann), scaled to the 80% target on 2023 and tested on 2024", "calibratedOn": { "companyYears": 1471, "sizeBand": "$10B+", "fitYears": [ 2018, 2022 ], "tuneYear": 2023, "testYear": 2024, "coverageOnTestYear": 0.8341, "coverageAllYears": 0.6904374799277399, "stressCoverageAllYears": 0.819004992974709, "outcomeYears": [ 2019, 2025 ] }, "credibility": { "weightOnOwnRecord": 0.5, "growthYears": 4, "ownVolatility": 0.09748860683773106, "classVolatility": 0.06659579566308972, "pricedVolatility": 0.08348361654588791, "k": 3 }, "stress": { "low": 9277439115.957426, "high": 14089692842.388687, "basis": "the same range with widths set to hold 80% across 2018-2023, pandemic years included" }, "kind": "a statistical range, not company guidance; no view on the share price", "track": { "backtest": { "tests": 15, "hits": 11, "rate": 0.7333333333333333, "method": "v4", "byYear": { "2011": [ 1, 1 ], "2012": [ 1, 1 ], "2013": [ 1, 1 ], "2014": [ 1, 1 ], "2015": [ 1, 1 ], "2016": [ 1, 1 ], "2017": [ 1, 1 ], "2018": [ 1, 1 ], "2019": [ 1, 1 ], "2020": [ 0, 1 ], "2021": [ 1, 1 ], "2022": [ 0, 1 ], "2023": [ 1, 1 ], "2024": [ 0, 1 ], "2025": [ 0, 1 ] }, "note": "hindsight: the same credibility-weighted range on the company's own past years. Years 2018-2023 were used to fit or tune the method, so only 2025 outcomes are fully out of sample." }, "registry": { "logged": "2026-10-07T14:22:46.846Z", "hash": "8c1a5e4659ddf606", "status": "open" }, "scorecard": "https://www.pops4.com/boards/scorecard" } }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001022079.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1022079" }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.1709, "growth3y": 0.0374, "volatility": 0.0975, "paysDividend": true, "raisedDividend": true, "equityRatio": 0.4419, "quadrant": { "code": "sj", "label": "Slow and jumpy", "plain": "growing slower than its size class, with revenue that swings more" }, "compass": { "code": "between", "inside": "Turns 17.1% of revenue into operating cash; revenue growing 3.7% a year over three years; pays and raised its dividend.", "outside": "Among $10B+ companies: 59th percentile for cash, 46th for growth.", "emoji": "🌊", "label": "In between", "plain": "no clear cash pattern yet" }, "band": "$10B+", "cashPctInClass": 59, "growthPctInClass": 46, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "slowjumpy", "text": "slow and jumpy: growing slower than its size class, with revenue that swings more" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 1886000000, "investing": -631000000, "financing": -1388000000, "capitalSpending": 527000000, "free": 1359000000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": 2233000000, "free": 1830000000 }, { "fiscalYearEnd": "2022-12-31", "operating": 1718000000, "free": 1314000000 }, { "fiscalYearEnd": "2023-12-31", "operating": 1272000000, "free": 864000000 }, { "fiscalYearEnd": "2024-12-31", "operating": 1334000000, "free": 909000000 }, { "fiscalYearEnd": "2025-12-31", "operating": 1886000000, "free": 1359000000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 420000000, "shortTerm": null, "longTerm": null, "equityHoldings": null, "totalAssets": 16225000000, "ladder": null, "currentRatio": 1.04, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same range method applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so.", "healthWatch": "Distress-type events the company filed in the last 12 months (late-filing notices; 8-K items 1.03, 3.01, 2.04, 4.02, 4.01, 2.05, 2.06, 1.05, 5.02), each with its count and newest filing. Display only: they do not change the range or its receipt." }, "speedCash": { "fiscalYear": 2025, "cashConversion": 0.1709, "growth3y": 0.0374, "volatility": 0.0975, "paysDividend": true, "raisedDividend": true, "equityRatio": 0.4419, "quadrant": { "code": "sj", "label": "Slow and jumpy", "plain": "growing slower than its size class, with revenue that swings more" }, "compass": { "code": "between", "inside": "Turns 17.1% of revenue into operating cash; revenue growing 3.7% a year over three years; pays and raised its dividend.", "outside": "Among $10B+ companies: 59th percentile for cash, 46th for growth.", "emoji": "🌊", "label": "In between", "plain": "no clear cash pattern yet" }, "band": "$10B+", "cashPctInClass": 59, "growthPctInClass": 46, "source": "SEC XBRL frames, the company’s own audited figures; quadrant split at the median of its size class" }, "harbor": { "signs": [ { "key": "slowjumpy", "text": "slow and jumpy: growing slower than its size class, with revenue that swings more" } ], "rule": "Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an 80% revenue range of ±25% or wider.", "level": 1, "name": "Sound ship", "plain": "one warning sign" }, "cashFlow": { "fiscalYearEnd": "2025-12-31", "operating": 1886000000, "investing": -631000000, "financing": -1388000000, "capitalSpending": 527000000, "free": 1359000000, "trend": [ { "fiscalYearEnd": "2021-12-31", "operating": 2233000000, "free": 1830000000 }, { "fiscalYearEnd": "2022-12-31", "operating": 1718000000, "free": 1314000000 }, { "fiscalYearEnd": "2023-12-31", "operating": 1272000000, "free": 864000000 }, { "fiscalYearEnd": "2024-12-31", "operating": 1334000000, "free": 909000000 }, { "fiscalYearEnd": "2025-12-31", "operating": 1886000000, "free": 1359000000 } ], "note": "Annual, as filed in 10-K cash flow statements; negative investing/financing = cash going out (capital spending, buybacks, dividends, debt repaid)." }, "investments": { "fiscalYearEnd": "2025-12-31", "cash": 420000000, "shortTerm": null, "longTerm": null, "equityHoldings": null, "totalAssets": 16225000000, "ladder": null, "currentRatio": 1.04, "unrealizedGain": null, "unrealizedLoss": null, "note": "Balance-sheet cash and investment securities at fiscal year end, as filed; short-term = due or saleable within a year. Insurers and banks hold most of their book here." }, "disclaimer": "Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners." }